Excellent post, rfc68. Many thanks. Three points you made struck me particularly, because they have arisen in posts over recent months, and your post reinforces these:
1. Prospective customers will have existing contracts and suppliers in place with proven technology and reliable tests. I think it was Mikrokosmos who related Joe Maeji commenting that we needed to recognise the 6 year cycle for adoption of new technology in this field. Having a better mousetrap will not in itself be necessarily sufficient. 2. Lower costs and convenience would be a good reason to move to new technology, such as with MixnGo. 3. I think it is Geoff who has said earlier that a prospect deciding to use MixnGo would be likely to apply it across its whole product range.
All of the above support good reasons for patience. Meanwhile, a slow and steady upward move in the share price, especially on lower turnover this time, is somewhat encouraging - at least to me.
And that's setting aside for the moment the potential for MixnGo outside this clinical field.
ADO Price at posting:
8.3¢ Sentiment: Buy Disclosure: Held
